Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer
2018
Multiphoton Phosphorescence Quenching Microscopy Reveals Kinetics of Tumor Oxygenation during Antiangiogenesis and Angiotensin Signaling Inhibition
2022 StandoutNobel
Hypoxia‐inducible factors: coupling glucose metabolism and redox regulation with induction of the breast cancer stem cell phenotype
2016 StandoutNobel
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Cancer–stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis
2012 StandoutNobel
Microenvironmental regulation of tumour angiogenesis
2017
Tumor angiogenesis: causes, consequences, challenges and opportunities
2019
Smarter drugs emerging in pancreatic cancer therapy
2014
Molecular imaging in drug development
2008 Standout
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2014 Standout
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
2011 Standout
Hepatocellular carcinoma
2018 Standout
Metabolic Symbiosis Enables Adaptive Resistance to Anti-angiogenic Therapy that Is Dependent on mTOR Signaling
2016
Pancreatic cancer
2020 Standout
Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer
2013
Burden of liver diseases in the world
2018 Standout
Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
2012 Standout
Vessel co-option in cancer
2019
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer
2015 StandoutNature
Head and neck cancer
2008 Standout
Advanced Intrahepatic Cholangiocarcinoma: Post Hoc Analysis of the ABC-01, -02, and -03 Clinical Trials
2019
PD-1/PD-L1 and immunotherapy for pancreatic cancer
2017
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Pancreatic cancer
2016 Standout
Hepatocellular carcinoma
2021 Standout
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
2021 Standout
Usefulness of 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: A meta-analysis
2009
The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors
2016
Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors
2014
FDG-PET in diagnosis, staging and prognosis of pancreatic carcinoma: A meta-analysis
2013
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
2014
Delivery technologies for cancer immunotherapy
2019 Standout
Ten years of anti-vascular endothelial growth factor therapy
2016
Pancreatic Adenocarcinoma
2014 Standout
Antiangiogenic therapy—evolving view based on clinical trial results
2012
From Krebs to clinic: glutamine metabolism to cancer therapy
2016 Standout
Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission Tomography
2000
Aptamers as targeted therapeutics: current potential and challenges
2016 Standout
Preclinical Mouse Cancer Models: A Maze of Opportunities and Challenges
2015
Transarterial therapies for hepatocellular carcinoma
2011
PET imaging of cellular proliferation
2005
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma
2021
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Early Detection, Curative Treatment, and Survival Rates for Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis: A Meta-analysis
2014
Oxidative Stress in Cancer
2020 Standout
Hepatocellular Carcinoma
2011
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
2011
Modeling and predicting clinical efficacy for drugs targeting the tumor milieu
2012
Basic and Therapeutic Aspects of Angiogenesis
2011 Standout
Antiangiogenic therapy in oncology: current status and future directions
2016
The immunology of hepatocellular carcinoma
2018
Measuring the Relationship of Quality of Life and Health Status, Including Tumor Burden, Symptoms, and Biochemical Measures in Patients with Neuroendocrine Tumors
2011
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
2011 Standout
Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma
2016
The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
2013
VEGF in Signaling and Disease: Beyond Discovery and Development
2019 Standout
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
2014
A phase I study of cabozantinib (XL184) in patients with renal cell cancer
2014 StandoutNobel
Predictive in vivo animal models and translation to clinical trials
2012
Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study
2020 Standout
Treatment of Liver Tumors with Lipiodol TACE: Technical Recommendations from Experts Opinion
2015
Hepatocellular carcinoma
2022 Standout
The Emerging Roles of Pericytes in Modulating Tumor Microenvironment
2021
LRG1 promotes angiogenesis by modulating endothelial TGF-β signalling
2013 StandoutNature
Micelle-Encapsulated Quantum Dot-Porphyrin Assemblies as in Vivo Two-Photon Oxygen Sensors
2015 StandoutNobel
Hepatocellular Carcinoma
2019 Standout
AASLD guidelines for the treatment of hepatocellular carcinoma
2017 Standout
Coordinating Radiometals of Copper, Gallium, Indium, Yttrium, and Zirconium for PET and SPECT Imaging of Disease
2010 Standout
NEMA NU2-2001 guided performance evaluation of four Siemens ECAT PET scanners
2004
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
Hepatocellular Carcinoma: Reasons for Phase III Failure and Novel Perspectives on Trial Design
2014
Lanthanide-Activated Phosphors Based on 4f-5d Optical Transitions: Theoretical and Experimental Aspects
2017 Standout
Radionuclide therapy for hepatocellular carcinoma: indication, cost and efficacy.
2009
Safety and Toxicology of Magnolol and Honokiol
2018 Standout
Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity
2014
Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination
2013
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
2014 Standout
Inositol Polyphosphate Multikinase Inhibits Angiogenesis via Inositol Pentakisphosphate-Induced HIF-1α Degradation
2017 StandoutNobel
Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
2012
Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases
2018 Standout
Congestive heart failure risk in cancer patients treated with vascular endothelial growth factor tyrosine kinase inhibitors: a systematic review and meta‐analysis of 36 clinical trials
2014
Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
2013
Human pharmacokinetic and dosimetry studies of [(18)F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression.
2001
Imaging Tri-Fusion Multimodality Reporter Gene Expression in Living Subjects
2004 StandoutNobel
PET-based treatment planning in radiotherapy: a new standard?
2007
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
2017 Standout
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
T cell exclusion, immune privilege, and the tumor microenvironment
2015 StandoutScience
Diabetic Neuropathy: A Position Statement by the American Diabetes Association
2016 Standout
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013
American Society of Clinical Oncology Treatment of Unresectable Non–Small-Cell Lung Cancer Guideline: Update 2003
2003 Standout
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011
Construction and Validation of Improved Triple Fusion Reporter Gene Vectors for Molecular Imaging of Living Subjects
2007 StandoutNobel
Works of Ivan Borbath being referenced
Efficacy of the combination of long-acting release octreotide and tamoxifen in patients with advanced hepatocellular carcinoma: a randomised multicentre phase III study
2007
Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy
2005
Biliary cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
The Role of PPARγ in Hepatocellular Carcinoma
2008
131I-Labelled-iodized oil for palliative treatment of hepatocellular carcinoma
2005
Use of 5-[76Br]bromo-2'-fluoro-2'-deoxyuridine as a ligand for tumour proliferation: validation in an animal tumour model
2002
Attenuation correction in whole-body FDG oncological studies: the role of statistical reconstruction
1999
The HepCar registry: report on a one-year registration program of hepatocellular carcinoma (HCC) in Belgium. What is daily practice in HCC?
2006
Tumor and plasma biomarker analysis from the randomized controlled phase II trial (RCT) of tivantinib in second-line hepatocellular carcinoma (HCC).
2016
Tivantinib (ARQ 197) versus placebo in patients (Pts) with hepatocellular carcinoma (HCC) who failed one systemic therapy: Results of a randomized controlled phase II trial (RCT).
2012
Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study.
2013
Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib
2016
Prognostic value of the neutrophil-to-lymphocyte ratio in the ARQ 197-215 second-line study for advanced hepatocellular carcinoma
2017
Sunitinib (SU) in patients with advanced, progressive pancreatic neuroendocrine tumors (pNET): Final overall survival (OS) results from a phase III randomized study including adjustment for crossover.
2016
Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib
2016
Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study
2013
VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial
2021
Tivantinib in MET-high hepatocellular carcinoma patients and the ongoing Phase III clinical trial
2014